Ernexa Therapeutics Raises $10.5M via 21M-Share, $0.50 Offering with $0.68 Warrants
Ernexa Therapeutics has priced a best-efforts public offering of 21 million common shares and detachable warrants at $0.50 each, generating gross proceeds of $10.5 million. The warrants, exercisable immediately at $0.68, expire on the earlier of five years post-issuance or 180 days after first Phase 1 ERNA-101 cohort data release, with closing expected around February 10, 2026.
1. Offering Details
Ernexa Therapeutics launched a best-efforts registered public offering of 21 million common shares (or equivalents) plus warrants to purchase an additional 21 million shares at a combined price of $0.50 per unit. The company will issue warrants exercisable upon issuance at $0.68 per share, expiring on the earlier of the five-year anniversary of issuance or 180 days after public release of first cohort data from the Phase 1 ERNA-101 study.
2. Use of Proceeds and Timeline
Gross proceeds of approximately $10.5 million (before fees and expenses) are intended to support advancement of cell therapy development programs, working capital, and general corporate purposes. The offering is expected to close on or about February 10, 2026, subject to customary closing conditions, with potential additional proceeds of $14.3 million if all warrants are exercised on a cash basis.